IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1257.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 24-Oct-2016
Precision medicine test helps guide breast cancer patients' chemotherapy decision
One of the earliest widespread applications of precision medicine in cancer care is helping patients and physicians decide whether chemotherapy is needed, a new study finds.
NIH/National Cancer Institute

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 24-Oct-2016
Study indicates that advances in precision medicine have improved breast cancer treatment
A new study examines how one early example of precision medicine -- tumor genome testing -- is being used in women with breast cancer to reduce overtreatment and maximize the benefits of chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that physician recommendations and final treatment decisions correlated highly with test results, suggesting genome testing helped physicians identify which patients could most benefit from chemotherapy, and those for whom chemotherapy could be safely omitted.

Contact: Dawn Peters

Public Release: 24-Oct-2016
Annals of Internal Medicine
New guideline on calcium and vitamin D supplementation
A new evidence-based clinical guideline from the National Osteoporosis Foundation and the American Society for Preventive Cardiology says that calcium with or without vitamin D intake from food or supplements that does not exceed the tolerable upper level of intake should be considered safe from a cardiovascular standpoint.

Contact: Cara Graeff
American College of Physicians

Public Release: 24-Oct-2016
Nature Genetics
Genetic hallmarks of acute lymphoblastic leukemia subtype uncovered
An international team of researchers from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP) and the Children's Oncology Group (COG) has identified the genetic changes that underpin a subtype of the most common cancer found in children. This form of B-precursor acute lymphoblastic leukemia (B-ALL) features genetic changes to two transcription factors known as DUX4 and ERG, proteins that closely control the activities of other crucial genes in human blood cells.

Contact: Barry Whyte
St. Jude Children's Research Hospital

Public Release: 24-Oct-2016
Redox Biology
Boosting levels of known antioxidant may help resist age-related decline
Researchers have found that a specific detoxification compound, glutathione, helps resist the toxic stresses of everyday life -- but its levels decline with age and this sets the stage for a wide range of health problems. It may be possible to restore glutathione levels and help prevent some of the metabolic declines associated with aging.
National Institutes of Health

Contact: Tory Hagen
Oregon State University

Public Release: 24-Oct-2016
Journal of Clinical Investigation
Study suggests that autophagy inhibitors could improve efficacy of chemotherapies
This week in the JCI, research led by Jayanta Debnath at UCSF has shown that inhibiting autophagy does not impair the immune response to tumors during chemotherapy, providing support for the idea that combining autophagy inhibitors with certain chemotherapies may aid cancer treatment.
NIH/National Cancer Institute, DOD/Breast Cancer Research Program

Contact: Elyse Dankoski
JCI Journals

Public Release: 24-Oct-2016
JAMA Internal Medicine
What proportion of cancer deaths are attributable to smoking around the US?
The proportion of cancer deaths attributable to cigarette smoking varied across the United States but was highest in the South, where nearly 40 percent of cancer deaths in men were estimated to be connected to smoking in some states, according to a new article published online by JAMA Internal Medicine.

Contact: David Sampson
The JAMA Network Journals

Public Release: 24-Oct-2016
New subtypes of lung cancer can lead to personalized therapies with better outcome
Analysis of vast amounts of molecular data from a set of more than 1,000 non-small cell lung cancers identifies distinct subtypes, each with its own molecular profile and potentially different response to therapy.

Contact: Allison Huseman
Baylor College of Medicine

Public Release: 24-Oct-2016
Scientific Reports
Tumor markers can reveal lethality of bladder cancers, guide treatment
Tumor cells collected during the removal of a cancerous bladder and transplanted into mice with weakened immune systems could help physicians rapidly identify high-risk cancers, determine prognosis and refine the use of biomarkers to personalize care for patients with this common cancer.
Ludwig Cancer Research, Rosalind and Burton Spellman Family Cancer Fund, Foglia Foundation and Mr. and Ms. Vincent Foglia

Contact: John Easton
University of Chicago Medical Center

Public Release: 24-Oct-2016
Nature Medicine
Fighting cancer with the power of immunity
Researchers at MIT's Koch Institute for Integrative Cancer Research have developed a new strategy for using immunotherapy to treat cancer. The researchers used a combination of four different therapies to activate both branches of the immune system, producing a coordinated attack that led to the disappearance of large, aggressive tumors in mice.
Koch Institute, NIH/National Cancer Institute, National Institutes of Health, Dana-Farber/Harvard Cancer Center, The V Foundation, and The Ragon Institute

Contact: Sarah McDonnell
Massachusetts Institute of Technology

Public Release: 24-Oct-2016
Study determines efficacy of 2 drugs to treat a form of leukemia
Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.
Boston University, National Institutes of Health, Leukemia Research Foundation, St. Baldrick Foundation, Rally Foundation, Alex's Lemonade Stand Foundation

Contact: Gina DiGravio
Boston University Medical Center

Public Release: 24-Oct-2016
Scientific Reports
A key to unlocking the mystery of triple negative breast cancer
The study suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patient and may help them avoid unnecessary and invasive treatments. The researchers found that prolactin hormone was able to reduce the aggressive behavior of cancerous cells. It does so by decreasing their ability to divide and form new tumors.

Contact: Valerie Harvey
514-934-1934 x71381
McGill University Health Centre

Public Release: 21-Oct-2016
Discovery of blood biomarkers for early pancreatic cancer detection
Pancreatic cancer is one of the most lethal forms of cancer. Early detection is essential to improve prognoses. Working toward that goal, a collaboration of researchers in Japan has discovered proteins in the blood which improve the detection of pancreatic cancer. When used in combination with conventional pancreatic cancer biomarkers, it enables the diagnosis of early stage pancreatic cancer, which was previously thought to be difficult.
Project for Development of Innovative Research on Cancer Therapeutics, Practical Research for Innovative Cancer Control, Project for Cancer Research and Therapeutic Evolution, Japan Agency for Medical Research and Development

Contact: J. Sanderson, N. Fukuda
Kumamoto University

Public Release: 21-Oct-2016
Genes to Cells
Paving the road to drug discovery
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.

Contact: Kaoru Natori
Okinawa Institute of Science and Technology (OIST) Graduate University

Public Release: 21-Oct-2016
Clinical Cancer Research
Presence of certain oral bacterium in esophageal cancer samples associated with shorter survival
Among Japanese patients with esophageal cancer, those whose cancer tested positive for DNA from the bacterium Fusobacterium nucleatum had shorter cancer-specific survival compared with those whose cancer had no DNA from the bacterium.
SGH Foundation

Contact: Lauren Riley
American Association for Cancer Research

Public Release: 21-Oct-2016
Microvascular Research
Danish researchers behind new cancer images
A Danish research team has developed a new method for studying how a tracer is distributed in a cancer tumor via its extensive vascular network. The method can be used for studying closely the effect of medical treatment using cancer inhibitors.

Contact: Jens Vinge Nygaard
Aarhus University

Public Release: 21-Oct-2016
Cancer Research
New oncogene linked to prostate cancer in African Americans may lead to better diagnostic tools
The new oncogene MNX1 is more active in African American than in European American prostate cancer.

Contact: Jeannette Jimenez
Baylor College of Medicine

Public Release: 21-Oct-2016
A new view of the immune system
Pathogen epitopes are fragments of bacterial or viral proteins. Nearly a third of all existing human epitopes consist of two different fragments. Known as 'spliced epitopes', these types of epitopes have long been regarded as rare. The fact that they are so highly prevalent might, among other things, explain why the immune system is so highly flexible. Results from this study have been published in the current issue of the journal Science.*

Contact: Dr. Michele Mishto
Charité - Universitätsmedizin Berlin

Public Release: 21-Oct-2016
Study links changes in collagen to worse pancreatic cancer prognosis
A study in the current journal Oncotarget provides the first evidence linking a disturbance of the most common protein in the body with a poor outcome in pancreatic cancer.

Contact: Kevin W. Eliceiri
University of Wisconsin-Madison

Public Release: 21-Oct-2016
Combating drug resistance in acute myeloid leukemia with a ceramide-based therapeutic
Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered a mechanism that confers resistance to drugs used to treat certain types of acute myeloid leukemia. Targeting this pathway with a novel lipid-based therapeutic showed efficacy in a preclinical model of AML. These findings were reported in an article published in the Oct. 13, 2016 issue of Blood.
NIH/National Cancer Institute, NIH/National Institute of Dental and Craniofacial Research, James F. Bomar Myeloid Malignancy Research Fund held at the MUSC Hollings Cancer Center, Lipidomics Shared Resource

Contact: Heather Woolwine
Medical University of South Carolina

Public Release: 21-Oct-2016
Angewandte Chemie International Edition
Where does cisplatin bind?
Cisplatin is one of the most widely used agents in cancer chemotherapy. It cross-links DNA, which can kill cells. But which part of the genome is more affected, and which is less affected? A Chinese team have now set up a universal, genome-wide assay to detect the specific cisplatin action sites. In the journal Angewandte Chemie they report initial results, which support the notion that the mitochondrial genome is one of cisplatin's main targets.

Contact: Mario Mueller

Public Release: 20-Oct-2016
Novel mechanisms of action discovered for skin cancer medication Imiquimod
Imiquimod is a medication successfully used in the treatment of skin diseases. In addition to its known mechanism of action, it also triggers other processes in the body. Scientists at the Technical University of Munich (TUM) have succeeded in explaining the molecular fundamentals of these additional effects. The results also shine a new light on other known molecular processes which could indicate an approach to the treatment of inflammatory illnesses.

Contact: Paul Hellmich
Technical University of Munich (TUM)

Public Release: 20-Oct-2016
Journal of Medicinal Chemistry
Scientists build a better cancer drug to pass through blood-brain barrier
In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg -- Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.

Contact: Vanessa Wasta
Johns Hopkins Medicine

Public Release: 20-Oct-2016
New compound shows promise in treating multiple human cancers
A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
Servier collaboration, National Health and Medical Research Council of Australia, Leukemia and Lymphoma Society, Cancer Council Victoria, Kay Kendall Leukemia Fund, Victorian Cancer Agency, Australian Cancer

Contact: Vanessa Solomon
Walter and Eliza Hall Institute

Public Release: 20-Oct-2016
Scientific Reports
A novel noninvasive imaging probe for fast and sensitive detection of cancer
The ultimate goal of cancer diagnostics is to develop sensitive imaging techniques for reliable detection of tumor malignancy in the body. Scientists at Tokyo Institute of Technology have come close to achieving this goal by developing an injectable imaging probe that can specifically detect solid tumors based on the activity of hypoxia-inducible factor regulated by the ubiquitin-proteasome system.
Japan Society for the promotion of Science

Contact: Emiko Kawaguchi
Tokyo Institute of Technology

Showing releases 1-25 out of 1257.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases